跳至主要内容
临床试验/NCT01649817
NCT01649817已完成不适用

Multicenter REtrospective Study to Evaluate coMpliance to Therapy and Drug survIval of Tocilizumab (TCZ) in patientS With Moderate to Severe actIve rheumatOid Arthritis in routiNe Daily Clinical Practice (REMISSION II Study)

Hoffmann-La Roche0 个研究点目标入组 183 人开始时间: 2012年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
183
主要终点
Percentage of patients on RoActemra/Actemra at 6 months after initiating treatment

研究概览

简要总结

This multicenter, retrospective observational study will evaluate compliance an reasons for withdrawal in patients with moderate to severe active rheumatoid arthritis on treatment with intravenous RoActemra/Actemra (tocilizumab) in daily clinical practice. Data will be collected from each eligible patient over a period of 6 months.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients, >/= 18 years of age
  • Moderate to severe rheumatoid arthritis according to the revised 1987 ACR criteria at baseline
  • RoActemra/Actemra treatment must have been initiated 6 months prior to ICF signing
  • Patient eligible according to the summary of product characteristics (SPC) and routine clinical practice/European recommendations for the use of biologic DMARDs for the treatment of rheumatoid arthritis

排除标准

  • Rheumatic autoimmune disease other than RA
  • Participation in interventional clinical trials during the observational period

结局指标

主要结局

Percentage of patients on RoActemra/Actemra at 6 months after initiating treatment

时间窗: 12 months

次要结局

  • Frequency of withdrawal (according to reasons)(12 months)
  • Frequency of dose modifications(12 months)
  • Change in disease activity (DAS28)(from baseline to Month 6 or withdrawal, whichever comes first)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验